Connect with us

Hi, what are you looking for?


Pfizer vaccine production on the rise as pandemic hits one-year mark

Stock Markets10 minutes ago (Mar 11, 2021 02:06PM ET)


(C) Reuters. FILE PHOTO: Coronavirus disease (COVID-19) vaccination campaign in Stains


By Michael Erman

NEW YORK (Reuters) – Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) will exceed their original global target for COVID-19 vaccines by as much as 20% this year, producing 2.3 billion to 2.4 billion doses, Pfizer Chief Executive Albert Bourla said on Thursday.

The companies also released real-world data from Israel earlier on Thursday showing their vaccine was 94% effective in preventing asymptomatic infections, suggesting it could significantly reduce virus transmission.

“These are stunning numbers that are giving us a clear indication that liberation is coming,” Bourla said in an interview on the one-year anniversary of the World Health Organization declaring COVID-19 a pandemic. “It is a testament to the power of science, and the power of human ingenuity.”

More than 2.7 million people around the world have died from COVID-19 so far.

Bourla said that by the fourth quarter of this year, Pfizer and BioNTech will reach a 3 billion dose a year production run rate, and should be able to produce that much next year.

The companies will clearly exceed their original target of 2 billion doses in 2021, he said.

Pfizer has said it expects revenue of at least $15 billion from its half of the vaccine sales this year.

Middle-income countries will pay around half the price as high income countries for their doses, and low income countries will get the vaccine at cost, Bourla said.

Pfizer expects to meet its commitment of supplying 120 million coronavirus vaccine doses to the U.S. government by the end of March. That would require them to deliver another 60 million doses over the next three weeks.

“Those have already been manufactured” and are currently being tested for quality, he said.

“Unless a batch (of vaccine) fails, we will be able to provide them. Our track record is that our batches don’t fail,” he said.

Pfizer’s German partner BioNTech began developing the vaccine last January and the U.S. drugmaker signed on in early March as the health crisis accelerated. Their vaccine received its first regulatory authorizations in December.

In the United States, the vaccine is authorized for use in people aged 16 or older. Bourla said the company plans to submit data for children aged 12 to 16 very soon.

He said his assumption was that the vaccine should be authorized for that age range by the fall, adding that data on children aged 5 to 11 can be expected by year-end.

Pfizer vaccine production on the rise as pandemic hits one-year mark

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.


Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione.


Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum.


At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.

Disclaimer: it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial or health advice. Copyright © 2021 Buzz Clever. All Rights Reserved